Back rskov, C, Holst JJ (April 1987) 'Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2)', Scandinavian Journal of Clinical and Laboratory Investigation , 47/2, 165-74.Back rskov, C, Holst, JJ, Seier Poulsen, S, Kirkegaard, P (Nov 1987) 'Pancreatic and intestinal processing of proglucagon in man', Diabetologia, 30, 874-81
10.1016/j.freeradbiomed.2021.03.046 Free Radic Biol Med
Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al
Self-pay and cash-pay patients For patients without insurance coverage or who choose to pay out of pocket, the billing complexity drops dramatically
